iShares Core Growth Allocation ETF vs Revvity Inc — how do they compare? iShares Core Growth Allocation ETF trades at $70.05, while Revvity Inc trades at $114.95 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while iShares Core Growth Allocation ETF pays none. Which is the better fit depends on your goals.
| AOR | RVTY | |
|---|---|---|
52-Week High | $70.12 | $117.75 |
52-Week Low | $62.26 | $82.26 |
Market Cap | — | $12.91B |
Sector | — | Technology |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
AOR, the iShares Core Growth Allocation ETF, trades at $69.87, showing minimal daily movement. Technical indicators are bullish based on moving averages, though the RSI suggests potential overbought conditions. The fund maintains a fixed 60/40 stock/bond allocation, offering a low-cost, diversified core holding strategy with a 20 basis point fee.
The outlook for AOR is stable, providing a straightforward asset allocation tool for long-term investors. Key risks include underperformance versus pure equity indices like the S&P 500 over extended periods, as noted by financial media, and sensitivity to interest rate changes affecting the bond portion.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →